StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for RCEL yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $4.52 | $4.19 | -7.30% | 0.4M |
| 05-19 | $4.12 | $4.20 | +1.82% | 0.2M |
| 05-20 | $4.27 | $4.32 | +1.17% | 0.2M |
| 05-21 | $4.23 | $4.48 | +5.91% | 0.2M |
| 05-22 | $4.61 | $4.58 | -0.65% | 0.2M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $19.06M | $70.88M | $53.45M | $36.55M |
Operating Income | $-8.80M | $-42.53M | $-32.13M | $-22.98M |
Net Income | $-10.61M | $-48.59M | $-36.97M | $-23.78M |
EPS (Diluted) | $-0.35 | $-1.74 | $-1.37 | $-0.90 |
Total Assets | $51.54M | $56.39M | $63.73M | $58.13M |
Total Liabilities | $74.71M | $73.04M | $70.39M | $70.98M |
Cash & Equivalents | $8.31M | $10.24M | $15.42M | $12.22M |
Free Cash Flow OCF − CapEx | $-10.09M | $-32.20M | $-27.44M | $-21.28M |
Shares Outstanding | 30.78M | 30.57M | 30.49M | 26.61M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.